The Geriatric Nutritional Risk Index Predicts Tolerability of Lenvatinib in Patients With Hepatocellular Carcinoma

Overview

Journal In Vivo

Specialty Oncology

Date 2022 Mar 4

PMID 35241544

Authors

Akiyoshi Kinoshita

Noriko Hagiwara

Akiyuki Osawa

Takafumi Akasu

Yoshihiro Matsumoto

Kaoru Ueda

Chisato Saeki

Tsunekazu Oikawa

Kazuhiko Koike

Masayuki Saruta

Affiliations

Soon will be listed here.

Abstract

Background/aim: We aimed to investigate the association between The Geriatric Nutritional Risk Index (GNRI) and the tolerability of lenvatinib in patients with hepatocellular carcinoma (HCC).

Patients And Methods: We retrospectively evaluated 61 HCC patients treated with lenvatinib and compared those with low GNRI (≤98, n=26) to those with high GNRI (>98, n=35).

Results: The discontinuation of lenvatinib due to adverse events was more frequent in the low GNRI group (46.2%) than in the high GNRI group (17.1%) (p=0.014). Multivariate analysis revealed that low GNRI (p=0.014), hypothyroidism (model 1 p=0.021, model 2 p=0.013), and advanced age (p=0.026) were independently associated with the discontinuation of lenvatinib. The progression-free survival in the low GNRI group was significantly shorter than that in the high GNRI group (p=0.047).

Conclusion: The GNRI might be independently associated with the tolerability of lenvatinib in patients with HCC.

Citing Articles

Effect of Nutritional Index on Lenvatinib Treatment Retention Rates in Unresectable Hepatocellular Carcinoma.

Wakamatsu R, Nakayama M, Wakamatsu A, Yamashita Y, Suto H, Katsuragawa M In Vivo. 2025; 39(2):988-999.

PMID: 40010999 PMC: 11884448. DOI: 10.21873/invivo.13904.

Geriatric nutritional risk index and newly developed scoring system as prognosis prediction for unresectable hepatocellular carcinoma patients treated with lenvatinib.

Ohama H, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J Sci Rep. 2025; 15(1):72.

PMID: 39747852 PMC: 11696502. DOI: 10.1038/s41598-024-78539-4.

Evaluation of Lung Adverse Events Associated With Lenvatinib: A Post-marketing Surveillance Study.

Kanbayashi Y, Kaneko Y, Kobayashi M, Wakabayashi H, Shimizu T, Uchida M In Vivo. 2024; 39(1):346-352.

PMID: 39740919 PMC: 11705116. DOI: 10.21873/invivo.13834.

Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives.

Chen Y, Dai S, Cheng C, Chen L J Hematol Oncol. 2024; 17(1):130.

PMID: 39709431 PMC: 11663365. DOI: 10.1186/s13045-024-01647-1.

Roles of clinical application of lenvatinib and its resistance mechanism in advanced hepatocellular carcinoma (Review).

Ye G, Ye M, Jin X Am J Cancer Res. 2024; 14(9):4113-4171.

PMID: 39417171 PMC: 11477829. DOI: 10.62347/UJVP4361.

References

Bouillanne O, Morineau G, Dupont C, Coulombel I, Vincent J, Nicolis I . Geriatric Nutritional Risk Index: a new index for evaluating at-risk elderly medical patients. Am J Clin Nutr. 2005; 82(4):777-83. DOI: 10.1093/ajcn/82.4.777. View

Sasaki M, Miyoshi N, Fujino S, Ogino T, Takahashi H, Uemura M . The Geriatric Nutritional Risk Index predicts postoperative complications and prognosis in elderly patients with colorectal cancer after curative surgery. Sci Rep. 2020; 10(1):10744. PMC: 7329855. DOI: 10.1038/s41598-020-67285-y. View

Singal A, Nagar S, Hitchens A, Davis K, Iyer S . Real-world effectiveness of lenvatinib monotherapy among unresectable hepatocellular carcinoma patients in the USA. Future Oncol. 2021; 17(21):2759-2768. DOI: 10.2217/fon-2021-0242. View

Uojima H, Chuma M, Tanaka Y, Hidaka H, Nakazawa T, Iwabuchi S . Skeletal Muscle Mass Influences Tolerability and Prognosis in Hepatocellular Carcinoma Patients Treated with Lenvatinib. Liver Cancer. 2020; 9(2):193-206. PMC: 7206580. DOI: 10.1159/000504604. View

Takahashi A, Moriguchi M, Seko Y, Ishikawa H, Yo T, Kimura H . Impact of Relative Dose Intensity of Early-phase Lenvatinib Treatment on Therapeutic Response in Hepatocellular Carcinoma. Anticancer Res. 2019; 39(9):5149-5156. DOI: 10.21873/anticanres.13710. View

Ikeda K, Kudo M, Kawazoe S, Osaki Y, Ikeda M, Okusaka T . Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. J Gastroenterol. 2016; 52(4):512-519. PMC: 5357473. DOI: 10.1007/s00535-016-1263-4. View

Sangro B, Sarobe P, Hervas-Stubbs S, Melero I . Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021; 18(8):525-543. PMC: 8042636. DOI: 10.1038/s41575-021-00438-0. View

Cereda E, Vanotti A . The new Geriatric Nutritional Risk Index is a good predictor of muscle dysfunction in institutionalized older patients. Clin Nutr. 2006; 26(1):78-83. DOI: 10.1016/j.clnu.2006.09.007. View

Kanno H, Goto Y, Sasaki S, Fukutomi S, Hisaka T, Fujita F . Geriatric nutritional risk index predicts prognosis in hepatocellular carcinoma after hepatectomy: a propensity score matching analysis. Sci Rep. 2021; 11(1):9038. PMC: 8079680. DOI: 10.1038/s41598-021-88254-z. View

10.

Kanehira D, Koinuma M, Kato T, Abe T, Sagara A, Sato F . Relationship between Low Pretreatment Geriatric Nutritional Risk Index and Poor Tolerability of Azacitidine in Patients with Myelodysplastic Syndromes. Ann Nutr Metab. 2021; 76(6):405-412. DOI: 10.1159/000513542. View

11.

Sonehara K, Tateishi K, Araki T, Komatsu M, Yamamoto H, Hanaoka M . Prognostic value of the geriatric nutritional risk index among patients with previously treated advanced non-small cell lung cancer who subsequently underwent immunotherapy. Thorac Cancer. 2021; 12(9):1366-1372. PMC: 8088948. DOI: 10.1111/1759-7714.13909. View

12.

Go S, Kim H, Kang M, Park S, Lee G . Prognostic model based on the geriatric nutritional risk index and sarcopenia in patients with diffuse large B-cell lymphoma. BMC Cancer. 2020; 20(1):439. PMC: 7236094. DOI: 10.1186/s12885-020-06921-2. View

13.

Tamai T, Hayato S, Hojo S, Suzuki T, Okusaka T, Ikeda K . Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure-Response Analyses. J Clin Pharmacol. 2017; 57(9):1138-1147. PMC: 5575539. DOI: 10.1002/jcph.917. View

14.

Ikeda S, Yoshioka H, Ikeo S, Morita M, Sone N, Niwa T . Serum albumin level as a potential marker for deciding chemotherapy or best supportive care in elderly, advanced non-small cell lung cancer patients with poor performance status. BMC Cancer. 2017; 17(1):797. PMC: 5704395. DOI: 10.1186/s12885-017-3814-3. View

15.

Li L, Wang H, Yang J, Jiang L, Yang J, Wu H . Geriatric nutritional risk index predicts prognosis after hepatectomy in elderly patients with hepatitis B virus-related hepatocellular carcinoma. Sci Rep. 2018; 8(1):12561. PMC: 6105611. DOI: 10.1038/s41598-018-30906-8. View

16.

Shoji F, Matsubara T, Kozuma Y, Haratake N, Akamine T, Takamori S . Relationship Between Preoperative Sarcopenia Status and Immuno-nutritional Parameters in Patients with Early-stage Non-small Cell Lung Cancer. Anticancer Res. 2017; 37(12):6997-7003. DOI: 10.21873/anticanres.12168. View

17.

Chang L, Hung S, Li J, Chiu K, Yang C, Chen C . Geriatric Nutritional Risk Index as a Prognostic Marker for Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Docetaxel. Front Pharmacol. 2021; 11:601513. PMC: 7868324. DOI: 10.3389/fphar.2020.601513. View

18.

Kudo M, Finn R, Qin S, Han K, Ikeda K, Piscaglia F . Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018; 391(10126):1163-1173. DOI: 10.1016/S0140-6736(18)30207-1. View

19.

Hiraoka A, Michitaka K, Kumada T, Izumi N, Kadoya M, Kokudo N . Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function. Liver Cancer. 2017; 6(4):325-336. PMC: 5704689. DOI: 10.1159/000479984. View

20.

Sasaki R, Fukushima M, Haraguchi M, Miuma S, Miyaaki H, Hidaka M . Liver Function in Older Patients With Unresectable Hepatocellular Carcinoma After Administration of Lenvatinib. Anticancer Res. 2021; 41(4):2025-2032. DOI: 10.21873/anticanres.14970. View